Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WALCURE trial
jRCTs041230019Phase 2Recruiting
- Sponsor
- Nihon Servier
- Start
- Jun 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine, paclitaxel, nanoliposomal irinotecan, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC) and pancreatic adenosquamous carcinoma (PASC) (2 cohorts), sponsored by Nihon Servier. Primary endpoint: Overall survival in resectable pancreatic cancer. Started Jun 2023; status: recruiting.
02
Drugs
gemcitabinepaclitaxelnanoliposomal irinotecanfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic adenosquamous carcinoma (PASC)
Beyond the preview
Go deeper on jRCTs041230019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041230019.